Subfulminant hepatitis B during treatment with adalimumab  in a patient with rheumatoid arthritis and chronic hepatitis B.
Verhelst
Xavier
X
Department of Gastroenterology and Hepatology, Ghent University Hospital, De Pintelaan 185, Ghent B-9000, Belgium. xavierverhelst@gmail.com
Orlent
Hans
H
Colle
Isabelle
I
Geerts
Anja
A
De Vos
Martine
M
Van Vlierberghe
Hans
H
D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D006515:Hepatitis B virus / Q000502:physiology*; D019694:Hepatitis B, Chronic / Q000821:virology*; D006801:Humans; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D014775:Virus Activation
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab